NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ORCHPHARMA · data 2026-10-31
Orchid Pharma Limited
In plain words
Price: 26.9% below its 52-week high of ₹1,143.5.
Delivery: 46.7% of traded shares were kept for delivery over the last 10 sessions, against 47.6% over the last 60.
Latest results: a net profit of ₹3 cr for the quarter ended Jun 2026 (-78.4% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹943 cr |
| Net profit (last 12 months) | ₹9 cr |
| Sales growth, 3 years (yearly) | 22.7% |
| Profit growth, 3 years (yearly) | -40.1% |
At a glance
Promoters 74.5% (+4.6 pts in a year), pledged 0.0%, institutions 18.4%.
P/E 489.5, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 0.7%, ROCE 0.2%, operating margin 0.3%: how much profit it earns on the money it uses.
Debt/equity 0.20, Profit growth -40.1% and sales growth 22.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Promoters raised their holding by 4.6 points in a year.
- Low return on equity (0.7%).
- Thin operating margin (0.3%).
- Profit fell 40.1% a year over 3 years.
- Expensive on earnings (P/E 489.5).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ORCHPHARMA Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹304.17 crore, up 75.9% YoY and down 17.4% QoQ.
Net profit was ₹3.22 crore, down 78.4% YoY and down 87.5% QoQ.
Operating margin was 4.6% (8.2% a year ago).
EPS was ₹0.54, down 81.6% YoY and down 87.5% QoQ.
ORCHPHARMA के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹304.17 करोड़; पिछले साल की तुलना में 75.9% की बढ़त, पिछली तिमाही की तुलना में 17.4% की गिरावट।
शुद्ध मुनाफ़ा: ₹3.22 करोड़; पिछले साल की तुलना में 78.4% की गिरावट, पिछली तिमाही की तुलना में 87.5% की गिरावट।
ऑपरेटिंग मार्जिन: 4.6% (एक साल पहले 8.2%)।
EPS: ₹0.54; पिछले साल की तुलना में 81.6% की गिरावट, पिछली तिमाही की तुलना में 87.5% की गिरावट।
ORCHPHARMAના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹304.17 કરોડ; ગયા વર્ષની સરખામણીએ 75.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 17.4% ઘટાડો.
ચોખ્ખો નફો: ₹3.22 કરોડ; ગયા વર્ષની સરખામણીએ 78.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 87.5% ઘટાડો.
ઓપરેટિંગ માર્જિન: 4.6% (એક વર્ષ પહેલાં 8.2%).
EPS: ₹0.54; ગયા વર્ષની સરખામણીએ 81.6% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 87.5% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 44.6% over the last 20 sessions vs 43.4% in the 40 before (1.03x); shares delivered per day 0.77x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 14 Aug 26Results Q1 FY27 results: profit −78.4% YoY -3.4% next session
- 14 Aug 26Results Q4 FY26 results: profit +15.9% YoY -3.4% next session
- 11 Feb 26Results Q3 FY26 results: turned to loss vs a year ago -2.4% next session
- 11 Nov 25Results Q2 FY26 results: turned to loss vs a year ago -3.9% next session
- 12 Aug 25Results Q1 FY26 results: profit −49.2% YoY -1.5% next session
- 28 May 25Results Q4 FY25 results: profit −32.4% YoY -9.7% next session
- 13 Feb 25Results Q3 FY25 results: profit −29.4% YoY -23.5% next session
- 12 Nov 24Results Q2 FY25 results: profit +37.6% YoY -0.1% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹304 cr | ₹3 cr | -78.4% | 4.6% | 0.54 |
| Mar 2026 | ₹368 cr | ₹26 cr | +15.9% | 8.2% | 4.31 |
| Dec 2025 | ₹207 cr | ₹-13 cr | -160.7% | 0.8% | -2.49 |
| Sept 2025 | ₹194 cr | ₹-6 cr | -121.0% | -0.8% | -1.13 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 74.45% | 69.84% | 69.84% | 69.84% |
| Foreign institutions (FII) | 0.93% | 0.81% | 0.87% | 1.17% |
| Domestic institutions (DII) | 17.44% | 20.75% | 20.25% | 19.39% |
| Mutual funds | 16.88% | 19.93% | 19.43% | 18.01% |
| Retail investors | 4.49% | 5.21% | 5.71% | 5.69% |
| Number of shareholders | 33,790 | 33,433 | 35,118 | 35,709 |
Common questions
What was Orchid Pharma Limited's latest quarterly profit?
Orchid Pharma Limited reported a net profit of ₹3 cr for the quarter ended Jun 2026 (-78.4% on the same quarter a year earlier), on revenue of ₹304 cr.
How much do promoters hold in Orchid Pharma Limited?
Promoters held 74.45% of Orchid Pharma Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Orchid Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0.2.
What is Orchid Pharma Limited's P/E ratio?
About 489.5, based on the last 12 months' earnings and a price of ₹836.45 (data 2026-10-31).
What is the 52-week high and low of Orchid Pharma Limited?
The 52-week high is ₹1,143.5 and the 52-week low is ₹480.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Orchid Pharma Limited | ₹836.45 | ₹4,989 cr | 489.5 | — | 0.7% | 0.2% | 0.2 | +17.4% |
| Sun Pharma Advanced Research Co. Ltd. | ₹176.46 | ₹5,741 cr | 3.6 | — | 276.9% | 232.1% | 0.42 | +27.9% |
| Senores Pharmaceuticals Ltd. | ₹1,133.9 | ₹5,221 cr | 39.2 | 5.2 | 13.4% | 12.6% | 0.37 | +46.7% |
| SMS Pharmaceuticals Limited | ₹511.35 | ₹4,793 cr | 45.4 | — | 14.3% | 13.9% | 0.46 | +77.2% |
| Gujarat Themis Biosyn Ltd | ₹363.2 | ₹4,718 cr | 81.3 | — | 17.4% | 18.2% | 0.56 | -21.9% |
| RPG Life Sciences Limited | ₹2,575.7 | ₹4,255 cr | 35.6 | — | 20.3% | 21.3% | 0.03 | +5.3% |
Compare ORCHPHARMA with SPARC in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ORCHPHARMA in NSE Scanner →